Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 10/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 9/20 | 0.50 |
| ▸ | TACR1 | P25103 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 2/20 | 0.47 |
| ▸ | ECE1 | P42892 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ITGAV | P06756 | 1/20 | 0.47 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29664049 | 1.00 | ITGB3 (0.50) | ITGB3ITGA2BTACR1PPARGPPARA | |
| SCHEMBL17685870 | 1.00 | ITGB3 (0.50) | ITGB3ITGA2BTACR1PPARGPPARA | |
| SCHEMBL23069521 | 0.96 | TACR1 (0.51) | ITGB3ITGA2BTACR1MMEECE1 | |
| SCHEMBL23069520 | 0.96 | TACR1 (0.51) | ITGB3ITGA2BTACR1MMEECE1 | |
| SCHEMBL29653507 | 0.94 | TACR1 (0.49) | ITGB3ITGA2BTACR1PPARGPPARA | |
| SCHEMBL23086004 | 0.92 | TACR1 (0.47) | ITGB3ITGA2BTACR1PPARGMEN1 | |
| SCHEMBL17685865 | 0.92 | KYNU (0.50) | TACR1PPARGMEN1KMT2ACTSL | |
| SCHEMBL17685866 | 0.92 | KYNU (0.50) | TACR1PPARGMEN1KMT2ACTSL | |
| SCHEMBL23069517 | 0.92 | ITGB3 (0.52) | ITGB3ITGA2BTACR1GPR132MME | |
| SCHEMBL23069519 | 0.92 | ITGB3 (0.52) | ITGB3ITGA2BTACR1GPR132MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220362386-A1 | LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF | NEURODERM LTD (IL) | 2022-11-17 | — | — | US | disclosed |
| EP-4025200-A1 | LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF | Neuroderm Ltd (IL) | 2022-07-13 | — | — | EP | disclosed |
| WO-2021044420-A1 | LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF | NEURODERM, LTD. (IL) | 2021-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220362386-A1 | LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF | DAO, DDC, AADAT | ITGB3 3733/4885ITGA2B 2850/4885TACR1 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.